語系:
繁體中文
English
說明(常見問題)
圖資館首頁
登入
回首頁
切換:
標籤
|
MARC模式
|
ISBD
Drug adherence in hypertension and c...
~
Burnier, Michel.
Drug adherence in hypertension and cardiovascular protection
紀錄類型:
書目-電子資源 : Monograph/item
正題名/作者:
Drug adherence in hypertension and cardiovascular protectionedited by Michel Burnier.
其他作者:
Burnier, Michel.
出版者:
Cham :Springer International Publishing :2018.
面頁冊數:
viii, 314 p. :digital ;24 cm.
Contained By:
Springer eBooks
標題:
Patient compliance.
電子資源:
http://dx.doi.org/10.1007/978-3-319-76593-8
ISBN:
9783319765938$q(electronic bk.)
Drug adherence in hypertension and cardiovascular protection
Drug adherence in hypertension and cardiovascular protection
[electronic resource] /edited by Michel Burnier. - Cham :Springer International Publishing :2018. - viii, 314 p. :digital ;24 cm. - Updates in hypertension and cardiovascular protection,2366-4606. - Updates in hypertension and cardiovascular protection..
1 Taxonomy of adherence -- I Measuring drug adherence -- 2 Qualitative assessment of adherence -- 3 Electronic monitoring of drug adherence -- 4 Measurements of drugs in plasma/urine -- 5 Assessing adherence measurement in large databases -- 6 Direct observed treatment in hypertension -- 7 Novel technologies for following drug adherence -- 8 Ethical aspects of measuring adherence II Risk factors for non-adherence -- 9 Determinants and barriers to adherence in CV diseases -- 10 Beliefs and adherence -- III Adherence in hypertension and CV protection -- 11 Impact of drug adherence in clinical trials -- 12 Drug adherence in essential hypertension: impact of drugs -- 13 Persistence in hypertension in general practice -- 14 Drug adherence in resistant hypertension -- 15 Drug adherence with cardiovascular medicines (statins) -- 16 Adherence and cardiovascular risk -- IV Interventions to improve drug adherence -- 17 Which interventions are useful? -- 18 Use of fixed-dose combinations in CV disease prevention -- 19 Nurse-led intervention in Hypertension -- 20 Role of the Pharmacist in supporting adherence -- 21 Integrated approaches to support adherence -- 22 Use of Apps to improve drug adherence -- V Health care consequences of non-adherence -- 23 Global clinical consequence of poor adherence -- 24 Cost of non-adherence.
This book provides a critical and comprehensive review of the methodologies available for measuring drug adherence in clinical practice, including those relying on emerging technologies. The authors discuss the risk factors of non-adherence and shed light on how to identify patients at risk of poor adherence. Drug therapies in chronic diseases rely heavily on the patient's adherence, since drugs that are not taken are ineffective and leave the patient at high risk of developing clinical complications. Given the absence of new drugs for the treatment of hypertension, drug adherence is particularly important in these patients to improve blood pressure control. The book further investigates a new aspect, namely the importance of drug adherence in clinical trials and studies and draws attention to the limits of developing drugs without significant information on drug adherence. Several chapters are dedicated to the importance of adherence in specific forms of hypertension, such as resistant hypertension, dyslipidemia and hypertension associated with cardiovascular risk. As experts confronted with drug adherence in their daily practice, the authors analyse the real effectiveness of several interventions aimed at improving drug adherence and put particular emphasis on the importance of an interdisciplinary approach involving nurses and pharmacists. The volume also includes a careful analysis of the health and economic impact of poor adherence. The book is aimed at physicians, pharmacists, students and all health professionals dealing not only with hypertension or dyslipidemia, but also with chronic asymptomatic diseases such as diabetes, HIV or chronic respiratory diseases.
ISBN: 9783319765938$q(electronic bk.)
Standard No.: 10.1007/978-3-319-76593-8doiSubjects--Topical Terms:
210817
Patient compliance.
LC Class. No.: R727.43 / .D784 2018
Dewey Class. No.: 615.5
Drug adherence in hypertension and cardiovascular protection
LDR
:04049nmm a2200325 a 4500
001
540856
003
DE-He213
005
20190111135742.0
006
m d
007
cr nn 008maaau
008
190308s2018 gw s 0 eng d
020
$a
9783319765938$q(electronic bk.)
020
$a
9783319765921$q(paper)
024
7
$a
10.1007/978-3-319-76593-8
$2
doi
035
$a
978-3-319-76593-8
040
$a
GP
$c
GP
041
0
$a
eng
050
4
$a
R727.43
$b
.D784 2018
072
7
$a
MJD
$2
bicssc
072
7
$a
MED010000
$2
bisacsh
082
0 4
$a
615.5
$2
23
090
$a
R727.43
$b
.D794 2018
245
0 0
$a
Drug adherence in hypertension and cardiovascular protection
$h
[electronic resource] /
$c
edited by Michel Burnier.
260
$a
Cham :
$b
Springer International Publishing :
$b
Imprint: Springer,
$c
2018.
300
$a
viii, 314 p. :
$b
digital ;
$c
24 cm.
490
1
$a
Updates in hypertension and cardiovascular protection,
$x
2366-4606
505
0
$a
1 Taxonomy of adherence -- I Measuring drug adherence -- 2 Qualitative assessment of adherence -- 3 Electronic monitoring of drug adherence -- 4 Measurements of drugs in plasma/urine -- 5 Assessing adherence measurement in large databases -- 6 Direct observed treatment in hypertension -- 7 Novel technologies for following drug adherence -- 8 Ethical aspects of measuring adherence II Risk factors for non-adherence -- 9 Determinants and barriers to adherence in CV diseases -- 10 Beliefs and adherence -- III Adherence in hypertension and CV protection -- 11 Impact of drug adherence in clinical trials -- 12 Drug adherence in essential hypertension: impact of drugs -- 13 Persistence in hypertension in general practice -- 14 Drug adherence in resistant hypertension -- 15 Drug adherence with cardiovascular medicines (statins) -- 16 Adherence and cardiovascular risk -- IV Interventions to improve drug adherence -- 17 Which interventions are useful? -- 18 Use of fixed-dose combinations in CV disease prevention -- 19 Nurse-led intervention in Hypertension -- 20 Role of the Pharmacist in supporting adherence -- 21 Integrated approaches to support adherence -- 22 Use of Apps to improve drug adherence -- V Health care consequences of non-adherence -- 23 Global clinical consequence of poor adherence -- 24 Cost of non-adherence.
520
$a
This book provides a critical and comprehensive review of the methodologies available for measuring drug adherence in clinical practice, including those relying on emerging technologies. The authors discuss the risk factors of non-adherence and shed light on how to identify patients at risk of poor adherence. Drug therapies in chronic diseases rely heavily on the patient's adherence, since drugs that are not taken are ineffective and leave the patient at high risk of developing clinical complications. Given the absence of new drugs for the treatment of hypertension, drug adherence is particularly important in these patients to improve blood pressure control. The book further investigates a new aspect, namely the importance of drug adherence in clinical trials and studies and draws attention to the limits of developing drugs without significant information on drug adherence. Several chapters are dedicated to the importance of adherence in specific forms of hypertension, such as resistant hypertension, dyslipidemia and hypertension associated with cardiovascular risk. As experts confronted with drug adherence in their daily practice, the authors analyse the real effectiveness of several interventions aimed at improving drug adherence and put particular emphasis on the importance of an interdisciplinary approach involving nurses and pharmacists. The volume also includes a careful analysis of the health and economic impact of poor adherence. The book is aimed at physicians, pharmacists, students and all health professionals dealing not only with hypertension or dyslipidemia, but also with chronic asymptomatic diseases such as diabetes, HIV or chronic respiratory diseases.
650
0
$a
Patient compliance.
$3
210817
650
0
$a
Hypertension
$x
Chemotherapy.
$3
819364
650
1 4
$a
Medicine & Public Health.
$3
273799
650
2 4
$a
Cardiology.
$3
273804
650
2 4
$a
Pharmacotherapy.
$3
615025
650
2 4
$a
Angiology.
$3
275861
650
2 4
$a
Metabolic Diseases.
$3
274217
650
2 4
$a
Diabetes.
$3
274215
700
1
$a
Burnier, Michel.
$3
819363
710
2
$a
SpringerLink (Online service)
$3
273601
773
0
$t
Springer eBooks
830
0
$a
Updates in hypertension and cardiovascular protection.
$3
750391
856
4 0
$u
http://dx.doi.org/10.1007/978-3-319-76593-8
950
$a
Medicine (Springer-11650)
筆 0 讀者評論
全部
電子館藏
館藏
1 筆 • 頁數 1 •
1
條碼號
館藏地
館藏流通類別
資料類型
索書號
使用類型
借閱狀態
預約狀態
備註欄
附件
000000160613
電子館藏
1圖書
電子書
EB R727.43 D794 2018 2018
一般使用(Normal)
在架
0
1 筆 • 頁數 1 •
1
多媒體
多媒體檔案
http://dx.doi.org/10.1007/978-3-319-76593-8
評論
新增評論
分享你的心得
Export
取書館別
處理中
...
變更密碼
登入